Parioforma market access capabilities statement 2014 vss

207
-1

Published on

Founded in 2000, Parioforma is an international business consultancy. We offer a consultancy-based approach and are proud of the strong, interactive and results-focused business partnerships we form with our clients.

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
207
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
7
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Parioforma market access capabilities statement 2014 vss

  1. 1. Market Access Capabilities Parioforma Ltd 55 Princes Gate Exhibition Road South Kensington London SW7 2PN United Kingdom www.parioforma.com
  2. 2. © 2014 Parioforma Ltd. About Parioforma • Founded in 2000, Parioforma is an international business consultancy. 2 We assist business units to maximise the return on research spending by tailoring projects to actual needs. In addition we interpret results into business implications – what does this mean for our client? We work with clients at the RFP stage to prioritise research requirements therefore helping them to focus on areas which will give them the greatest return. We offer a consultancy-based approach and are proud of the strong, interactive and results-focused business partnerships we form with our clients. Studies are frequently divided into phases providing a built- in flexibility to direct follow- on work according to the results of early findings – ensuring that resources remain focused. We specialise in custom research:
  3. 3. © 2014 Parioforma Ltd. Why work with Parioforma? 3 1. Bespoke studies – tailored needs and timelines.1. Bespoke studies – tailored needs and timelines. 2. Affordable pricing – making budgets go further.2. Affordable pricing – making budgets go further. 3. High quality research – experienced science-based team with 10-25+ years experience in Pharma/ Healthcare industries. 3. High quality research – experienced science-based team with 10-25+ years experience in Pharma/ Healthcare industries. 4. Unique problem solving approach – the Parioforma team is highly specialised, but diverse in experience and background, enabling analysis of problems from different perspectives. 4. Unique problem solving approach – the Parioforma team is highly specialised, but diverse in experience and background, enabling analysis of problems from different perspectives. 5. Strategic pointers & practical implementable solutions – not just “over-clever analysis.” Helps clients better understand the research and the implications for their business. 5. Strategic pointers & practical implementable solutions – not just “over-clever analysis.” Helps clients better understand the research and the implications for their business. Key benefits of working with Parioforma
  4. 4. © 2014 Parioforma Ltd. We cover traditional as well as emerging & complicated markets 4 From our London base we are able to provide a global footprint by utilising our extensive network of associates across: •North America •Western Europe •Australia & Japan In addition we have strong capabilities in emerging and complicated markets: •Central Europe, Baltic States, Russia & CIS •South East Europe including Turkey •Middle East & Africa •Latin America •India, Pakistan, Malaysia, Thailand, etc.
  5. 5. © 2014 Parioforma Ltd. What we do 5 • At Parioforma we believe that a successful Market Access Strategy begins with reliable intelligence. • We are focused on delivering ad hoc actionable global and local market access intelligence in the fields of pharmaceutical, biotechnology, IVD and medical devices. • We provide pragmatic and realistic solutions.
  6. 6. © 2014 Parioforma Ltd. Support services 6 • We specialize in-depth primary and secondary research to support ad hoc analysis – study design is driven by client needs. • Pricing and access strategy. • Revenue scenario testing. • Payer segmentation and partnership development. • Commercialization strategy. • Country specific market access understanding. • Value gap and value driver analysis. • Payer evidence generation. • Value message testing and value proposition development. • Early price potential assessment. • Profiling of disease , prescriber and payer environment. • Due diligence and commercial opportunity exploration. Phase II Phase III & Pre- Launch Preclinical & Phase I
  7. 7. © 2014 Parioforma Ltd. Our network 7 In-country KOL & payer panels Local experts & partners In-country boutique research agencies In addition to our core team, Parioforma has built up a global network of in-country partners and experts in the healthcare, pharmaceutical, IVD and medical device industries. •Parioforma has direct links with in-country KOLs and payers which can be accessed remotely from the UK. •The advantage of using local independent partners enables Parioforma to leverage deep knowledge and insights into national market situations. Parioforma Research Expertise
  8. 8. © 2014 Parioforma Ltd. Project examples 8 CLIENT ISSUE SOLUTION UK Global Pharmaceutical Company To understand the decision making process and evidence requirements for market access in selected CEE countries: key organizations, key individuals, etc. Key payer decision makers in each country were identified. A depth interview programme was carried out to establish the links, relationships and level of importance of each of the individuals and organizations involved. Results were interpreted for market access strategy. Top 5 Global Pharmaceutical Company To evaluate the role and development of HTA/ economic evaluations in support of evidence-based decision- making in selected emerging markets: CEE, Middle East, Latin America. The team conducted an in-depth interview programme with respondents from government agencies, ISPOR & INAHTA, academic health economists. As a result Parioforma were able to provide the client with country specific key HTA strategy pointers. Leading EU- Based Pharmaceutical Company To understand the current situation concerning the use and implementation of HTA/ economic evaluations for drug reimbursement and decision making in Russia. Extensive primary research was conducted across the country with ROSPOR, Roszdraznadzor, top clinical pharmacologists and foreign and domestic pharmacos. Results were leveraged to position Russia in the evolutionary path of using pharmaco- economics for setting government prices and reimbursement criteria.
  9. 9. © 2014 Parioforma Ltd. Project examples 9 CLIENT ISSUE SOLUTION Leading Japanese Pharmaceutical Company The need to understand the evidence required for pricing & reimbursement of dialysis treatments in selected emerging EU countries. The team identified key payer decision makers in each country and carried out a depth interview programme. Results were interpreted to provide strategy pointers for market access. UK-based Global Biotechnology Company New market entry. To establish a Central and Eastern European business by utilizing 3rd party distributors to build a strategic distribution network and create a CEE marketing channel for forthcoming products. The team leveraged its unique capability to undertake market intelligence and evaluation work in the CEE. Detailed analysis of the universe of distribution companies in the region was undertaken as well as an evaluation of the regulatory and healthcare environments of the component countries resulting in a short-list of priority potential partner companies. UK Top 5 Global Pharmaceutical Company The need to understand price controls and reimbursement barriers in selected emerging market economies - Russia, China, Indonesia and Poland. The team identified and profiled key KOLs and payers in each country. Local environments were mapped and an in-depth analysis of the pricing and reimbursement tactics was conducted. Results were interpreted to develop a generic model for exploiting price controls.
  10. 10. © 2014 Parioforma Ltd. Emerging market insights 10 • Pharma markets in emerging markets have been continuously witnessing robust growth on account of: – Increasing prevalence of diseases – Rising healthcare spending – Increasing affordability • Political and economic transition since the 1990s has resulted in many changes in the health sectors of these countries. • Many have adopted social health insurance (SHI) models in attempts to move away from centrally planned and state controlled healthcare financing and coverage. • Healthcare reforms have been accompanied by a need for increased spending driven by: – Economic growth – Ageing populations – Advances in medical technology – Expanding expectations on the part of national populations • Reforms and increased spending have brought new challenges highlighting the need for: – Cost containment – Improvements in quality of services – Improvements in equity of access – Assurance of rational and transparent spending decisions • Until recently, many countries have implemented new technologies with little or no regard for costs or effectiveness but increased attention is now being paid to the implementation of measures to manage costs and obtain better value for money: – Reimbursement and pricing controls – e.g. reference pricing systems – Establishment of positive lists – Cost sharing – e.g. co-payments – Adoption of the use of HTA in healthcare decision making – e.g. listing status, reimbursement level, pricing, practice guidelines – Emerging HTA guidelines
  11. 11. © 2014 Parioforma Ltd. Emerging market insights – HTA comparisons 11 APPROACH POLAND ISRAEL ARGENTINA Preferred or required assessment approach CEA CUA BIA CUA BIA CEA BIA Choice of comparator Most frequently used, most effective, least expensive, or no treatment Existing standard of care Most frequently used Principle outcome measures Mortality Morbidity Quality of life Mortality Morbidity Progression free survival Quality of life Mortality Morbidity Quality of life Costs All direct and indirect costs Direct costs Direct costs Modelling Yes Yes – simple only Yes – simple only Sensitivity analysis Yes Yes Yes Abbreviations: CEA – Cost Effectiveness Analysis; CUA – Cost Utility Analysis; BIA – Budget Impact Analysis
  12. 12. © 2014 Parioforma Ltd. Contact 12

×